Trial Profile

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO With Open-Label Safety Period in Pediatric Subjects With Epilepsy

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2025 Status changed from active, no longer recruiting to completed.
16 Apr 2025 According to a Neurelis media release, the company presented data on the study at the 53rd Annual Child Neurology Society Meeting in November 2024 in San Diego and Annual American Epilepsy Society Meeting in December 2024 in Los Angeles.
16 Apr 2025 According to a Neurelis media release, the USFDA has approved VALTOCO (diazepam nasal spray) for short-term treatment of seizure clusters (acute repetitive seizures) that are different from a person's normal seizure pattern in people 2 years of age and older.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com